查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2082563

幹細胞療法市場：2026-2032年全球市場預測（依療法、細胞來源、技術、給藥方法、應用、治療領域和最終用戶分類）

Stem Cell Therapy Market by Therapy Type, Cell Source, Technology, Mode of Administration, Application, Therapeutic Areas, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，幹細胞治療市場將成長至 133.5 億美元，複合年成長率為 14.79%。

主要市場統計數據
基準年 2025 50.8億美元
預計年份：2026年 57.9億美元
預測年份 2032 133.5億美元
複合年成長率 (%) 14.79%

幹細胞療法執行摘要

幹細胞療法正從一項專門的移植領域發展成為一個更廣泛的再生醫學平台，其目標涵蓋腫瘤學、整形外科、免疫學、眼科學、神經病學、骨科、皮膚病學以及罕見疾病等領域。目前最成熟的臨床應用仍是造血幹細胞移植，該療法擁有數十年的臨床證據支持，並已常規用於治療白血病、淋巴瘤、多發性骨髓瘤、骨髓衰竭和遺傳性血液疾病。同時，誘導多功能能幹細胞（iPS細胞）、間質支持細胞、神經幹細胞和基因修飾的前驅細胞正在拓展幹細胞療法市場，使其超越「替代生物學」的範疇，涵蓋免疫調節、組織修復和可擴展的細胞生產等領域。

幹細胞治療前景的變革性變化

幹細胞治療領域的格局正受到三大結構性變革的重塑：轉化科學的強化、監管力度的加強以及工業化規模生產的推進。儘管自體幹細胞療法在患者個別化治療至關重要的領域仍具有臨床價值，但異體幹細胞平台因其能夠實現標準化生產、庫存管理以及惠及更廣泛的患者群體而日益受到關注。這種轉變在急性疾病的治療中尤其重要，因為治療時機的選擇會直接影響治療結果。

人工智慧對幹細胞療法的累積影響

人工智慧 (AI) 正在對幹細胞治療的整個價值鏈產生累積影響，從藥物發現到商業化。在研究早期階段，AI 驅動的影像分析、體學資料整合和預測建模能夠實現分化狀態的識別、培養異常的檢測以及細胞表現型的比較，其規模遠遠超過人工審核。在製程開發階段，機器學習有助於最佳化培養基、控制生物反應器參數，並及早發現影響細胞活力、效力和產量的偏差。

幹細胞治療的關鍵區域見解

亞太地區正成為幹細胞治療研究最活躍的地區之一，這得益於中國、日本、韓國、印度、澳洲和新加坡等國不斷擴大的臨床試驗活動、再生醫學政策以及強大的生物醫藥製造能力。在日本，已建立起再生醫學產品的有條件、有時限的核准框架，為適應性發展創造了理想的環境。同時，在中國，隨著對幹細胞臨床研究的申請、倫理審查和產品註冊監管力度的加強，臨床研究生態系統也不斷改進。印度和澳洲則憑藉其成本效益高的臨床能力、高品質的轉化研究以及在進行臨床試驗方面嚴格的監管合規性，發揮互補優勢。

我們集團對全球幹細胞治療市場的主要觀點

隨著新加坡、泰國、馬來西亞、印尼、越南和菲律賓不斷加強其臨床研究體系、醫院認證、倫理審查和生物製造能力，東協市場在幹細胞治療領域的重要性日益凸顯。該地區的成長潛力取決於監管政策的明確、跨境臨床試驗合作、品管的細胞處理以及對未經證實的商業性幹細胞療法的更嚴格監管。在海灣合作理事會（GCC）地區，對專科醫院、基因組學、移植服務和先進醫療服務的投資正在催生對再生醫學領域夥伴關係的需求。預計最大的機會將出現在受監管的臨床試驗、經認證的細胞處理基礎設施以及基於循證醫學的患者轉診途徑。

主要國家幹細胞療法的發展趨勢

美國在幹細胞療法的商業化方面處於領先地位，其優勢包括：在FDA監管下的臨床試驗、移植網路、創業投資支持的生物技術、臍帶血基礎設施以及對先進製造的投資。另一方面，加拿大以其再生醫學研究網路、細胞療法生產計畫、公共臍帶血資源和規範的臨床開發而聞名。墨西哥是一個快速成長的區域市場，但為了抓住真正的商機，它需要更清晰地區分已獲批准的臨床研究和未經證實的幹細胞療法。巴西憑藉其在移植領域的豐富經驗、公共研究能力以及在先進療法監管方面的經驗，已成為拉丁美洲最重要的幹細胞治療中心。

為幹細胞治療領域的領導者提供的實用建議

產業領導者應優先考慮幹細胞療法具有有效作用機制、可衡量終點和明確未滿足需求的適應症。項目設計應基於符合監管標準的證據，包括健全的對照組、與臨床功能相關的療效檢測、長期追蹤研究以及透明的安全報告。各機構應避免做出廣泛的聲明，而是圍繞永續性、患者選擇、可生產性、安全監測和保險公司關注的關鍵結果，建構差異化的產品特性。

調查方法

本執行摘要採用結構化的二級調查方法編寫，並遵循檢驗的一級研究標準。分析整合了來自監管機構、同行評審的生物醫學文獻、臨床試驗註冊資料庫、健康技術評估 (HTA)資訊來源、移植和再生醫學組織、國家政策文件以及權威醫學協會指南的資訊。特別強調來自權威機構的已驗證證據，包括美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA)、美國國立檢驗研究院 (NIH)、ClinicalTrials.gov、世界衛生組織 (WHO) 以及頂級科學期刊的資源。

結論

幹細胞療法正進入一個更嚴謹的階段，科學前景必須經過臨床驗證、獲得監管部門批准，並最終轉化為經濟上永續的治療方案。最大的市場機會將屬於那些能夠將嚴謹的生物學研究和工業化生產與可靠的臨床證據、負責任的患者獲取策略以及透明的安全監測相結合的研發公司。造血幹細胞移植仍是臨床治療的基礎，而下一代異體移植、誘導性多能幹細胞衍生產品和基因修飾幹細胞產品正在塑造未來的治療產品線。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 幹細胞治療市場：依治療類型分類

  • 順勢療法
  • 自體療法

第8章 幹細胞療法市場：依細胞來源分類

  • 成體幹細胞
    • 造血幹細胞
    • 間質幹細胞
    • 神經幹細胞
  • 胚胎幹細胞
  • 誘導性多功能幹細胞
  • 周產期幹細胞
    • 羊水來源幹細胞
    • 臍帶幹細胞

第9章 幹細胞療法市場：依技術分類

  • 生物材料療法
  • 體外培養
  • 基因編輯技術
  • 利用支架進行治療

第10章 幹細胞療法市場：依給藥途徑分類

  • 關節內
  • 肌肉內部
  • 靜脈

第11章 幹細胞治療市場：依應用領域分類

  • 藥物發現與開發
  • 再生醫學
  • 組織工程

第12章 幹細胞治療市場：依治療領域分類

  • 心血管疾病
  • 血液學
  • 肌肉骨骼疾病
  • 神經病變
  • 腫瘤學

第13章 幹細胞治療市場：依最終使用者分類

  • 學術研究機構
  • 生物製藥公司
  • 醫院和診所
  • 幹細胞庫

第14章 幹細胞治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 幹細胞治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 幹細胞療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Anterogen Co., Ltd.
  • Astellas Pharma Inc.
  • Beike Biotechnology Co., Ltd.
  • BrainStorm Cell Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • CellProthera SAS
  • Cynata Therapeutics Limited
  • Fate Therapeutics, Inc.
  • Gamida Cell Ltd.
  • Garuda Therapeutics
  • Holostem Terapie Avanzate Srl
  • Jasper Therapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Juvena Therapeutics Inc.
  • Kangstem Biotech Co., Ltd.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Lonza Group AG
  • Medeze Group
  • Merck KGaA
  • Mesoblast Ltd.
  • Novo Nordisk A/S
  • Plasticell
  • Pluri Inc.
  • ReNeuron Group PLC
  • SQZ Biotechnologies Company by Stemcell Technologies
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • US Stem Cell Inc
  • Umoja Biopharma
  • Vericel Corporation
Product Code: MRR-431752EA49AD

The Stem Cell Therapy Market is projected to grow by USD 13.35 billion at a CAGR of 14.79% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.08 billion
Estimated Year [2026] USD 5.79 billion
Forecast Year [2032] USD 13.35 billion
CAGR (%) 14.79%

Stem Cell Therapy Executive Summary

Stem cell therapy is advancing from a specialized transplant discipline into a broader regenerative medicine platform for oncology, hematology, immunology, ophthalmology, neurology, orthopedics, dermatology, and rare diseases. The most established clinical use remains hematopoietic stem cell transplantation, supported by decades of clinical evidence and routinely used for leukemias, lymphomas, myeloma, bone marrow failure, and inherited blood disorders. At the same time, induced pluripotent stem cells, mesenchymal stromal cells, neural stem cells, and engineered progenitor cells are expanding the stem cell therapy market beyond replacement biology toward immune modulation, tissue repair, and scalable cell manufacturing.

Regulators are reinforcing the distinction between approved cell therapy products and unproven interventions. The U.S. FDA, European Medicines Agency, and other authorities continue to warn against clinics marketing unapproved stem cell treatments while supporting well-controlled clinical development through advanced therapy frameworks. For industry leaders, the opportunity is significant but evidence-dependent: durable clinical benefit, reproducible potency assays, GMP-compliant manufacturing, cryogenic logistics, and reimbursement readiness are now the defining factors for commercial success in stem cell therapy.

Transformative Shifts in the Stem Cell Therapy Landscape

The stem cell therapy landscape is being reshaped by three structural shifts: stronger translational science, tighter regulatory scrutiny, and industrial-scale manufacturing. Autologous approaches remain clinically valuable where patient-specific compatibility is essential, but allogeneic stem cell platforms are gaining attention because they can support standardized production, inventory availability, and broader patient access. This shift is especially important for acute indications where treatment timing can influence outcomes.

A second transformation is the move from procedure-based therapy to product-based regenerative medicine. Developers are investing in defined cell characterization, release testing, closed-system bioprocessing, and long-term safety monitoring. Meanwhile, hospitals and payers are demanding evidence from randomized trials, registries, and real-world outcomes before adoption. These changes favor organizations that can demonstrate mechanism of action, batch consistency, clinical durability, and health-economic value rather than relying on broad regenerative claims.

Cumulative Impact of Artificial Intelligence on Stem Cell Therapy

Artificial intelligence is creating a cumulative impact across the stem cell therapy value chain, from discovery through commercial operations. In early research, AI-enabled image analysis, omics integration, and predictive modeling help identify differentiation states, detect culture abnormalities, and compare cell phenotypes at a scale that manual review cannot match. In process development, machine learning can support media optimization, bioreactor parameter control, and early detection of deviations that affect cell viability, potency, and yield.

AI is also influencing clinical development. Protocol feasibility tools, biomarker stratification, digital pathology, and adverse-event signal detection can improve trial design and patient monitoring. However, AI in stem cell therapy must be validated against regulated quality systems, explainability expectations, and data integrity requirements. The strongest near-term value will come from auditable AI applications that reduce variability, improve manufacturing control, and accelerate evidence generation without compromising patient safety.

Key Regional Insights for Stem Cell Therapy

Asia-Pacific is becoming one of the most active regions for stem cell therapy research, supported by expanding clinical trial activity, regenerative medicine policies, and strong biomedical manufacturing capabilities in China, Japan, South Korea, India, Australia, and Singapore. Japan's conditional and time-limited approval framework for regenerative medical products has made it a reference environment for adaptive development, while China's clinical research ecosystem continues to scale under strengthened oversight for stem cell clinical research filing, ethics review, and product registration. India and Australia add complementary strengths through cost-sensitive clinical capacity, high-quality translational research, and regulated trial execution.

North America remains a global anchor for high-value stem cell therapy innovation because of its concentration of academic medical centers, FDA-regulated clinical trials, venture funding, contract development and manufacturing organizations, cord blood and donor registries, and transplant infrastructure. Europe is shaped by the EMA's advanced therapy medicinal product framework, strong public research networks, national health technology assessment systems, and increasing investment in cell therapy manufacturing capacity. Latin America, led by Brazil and Mexico, is growing through transplant programs and clinical research partnerships, although reimbursement pathways and regulatory harmonization remain uneven. The Middle East is investing in medical tourism, tertiary care, genomics, and precision medicine infrastructure, particularly in GCC countries, while Africa's opportunity is tied to capacity building, ethical oversight, trained workforce development, and partnerships that expand access to proven therapies such as hematopoietic stem cell transplantation.

Key Group Insights Across Global Stem Cell Therapy Markets

ASEAN markets are increasingly relevant for stem cell therapy because Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines are strengthening clinical research ecosystems, hospital accreditation, ethics review, and biomanufacturing ambitions. The region's growth potential depends on regulatory clarity, cross-border trial collaboration, quality-controlled cell processing, and stronger controls against unproven commercial stem cell treatments. In the GCC, investment in specialty hospitals, genomics, transplant services, and advanced care delivery is creating demand for regenerative medicine partnerships, with the strongest opportunities in compliant clinical trials, accredited cell processing infrastructure, and evidence-based patient referral pathways.

The European Union provides one of the most structured regulatory environments through the ATMP pathway, making it attractive for developers that can meet rigorous quality, safety, efficacy, pharmacovigilance, and manufacturing requirements. BRICS countries combine large patient populations, expanding research capacity, public-sector science investment, and strategic interest in domestic biomanufacturing, but market access varies by country because of differences in regulatory maturity, reimbursement, and hospital infrastructure. G7 markets remain central to premium innovation, intellectual property creation, clinical trial quality, reimbursement evidence, and advanced manufacturing standards, while NATO countries benefit indirectly from resilient healthcare supply chains, biomedical security priorities, and coordinated standards that can support advanced therapy readiness.

Key Country Insights in Stem Cell Therapy

The United States leads stem cell therapy commercialization through FDA-supervised trials, transplant networks, venture-backed biotechnology, cord blood infrastructure, and advanced manufacturing investment, while Canada is recognized for regenerative medicine research networks, cell therapy manufacturing programs, public cord blood resources, and regulated clinical development. Mexico is a growing regional market, but credible opportunities depend on stronger differentiation between approved clinical research and unproven stem cell offerings. Brazil has meaningful transplant expertise, public research capabilities, and regulatory experience in advanced therapies, positioning it as Latin America's most important stem cell therapy hub.

In Europe, the United Kingdom combines academic excellence, clinical trial capability, cell therapy manufacturing initiatives, and a dedicated advanced therapy regulatory pathway. Germany and France bring major hospital systems, biomedical engineering depth, transplant expertise, and strict regulatory standards, while Italy and Spain contribute important transplant programs, regenerative medicine research, and hospital-based clinical development. Russia maintains scientific capability in cell biology and transplantation but faces market access, investment, and international collaboration constraints. In Asia-Pacific, China is scaling research and domestic development under tighter regulatory governance, India is expanding cost-sensitive clinical capacity and regenerative medicine research, Japan is shaped by regenerative medicine regulation and iPSC leadership, Australia offers high-quality trials and biomedical research infrastructure, and South Korea is a prominent innovator in cell therapy manufacturing, hospital translation, and regenerative medicine commercialization.

Actionable Recommendations for Stem Cell Therapy Leaders

Industry leaders should prioritize indications where stem cell therapy has a plausible mechanism, measurable endpoints, and a clear unmet need. Programs should be designed around regulatory-grade evidence, including robust comparators, potency assays linked to clinical function, long-term follow-up, and transparent safety reporting. Organizations should avoid broad claims and instead build differentiated product profiles around durability, patient selection, manufacturability, safety monitoring, and payer-relevant outcomes.

Operationally, leaders should invest early in scalable GMP manufacturing, closed-system processing, cryopreservation validation, chain-of-identity and chain-of-custody controls, contamination prevention, and qualified logistics partners. Partnerships with academic centers, transplant networks, AI-enabled analytics providers, and contract development and manufacturing organizations can reduce development risk. Commercial teams should prepare reimbursement dossiers before launch by collecting health-economic data, real-world evidence plans, clinician training resources, and patient education materials that clearly distinguish approved stem cell therapies from unregulated interventions.

Research Methodology

This executive summary is developed using a structured secondary research methodology aligned with validated primary research standards. The analysis synthesizes information from regulatory agencies, peer-reviewed biomedical literature, clinical trial registries, health technology assessment sources, transplant and regenerative medicine organizations, national policy documents, and recognized medical society guidance. Emphasis is placed on verified evidence from recognized authorities such as the U.S. FDA, EMA, NIH resources, ClinicalTrials.gov, the World Health Organization, and major scientific publications.

The methodology prioritizes evidence triangulation across clinical, regulatory, manufacturing, and market-access dimensions. Insights are validated by comparing multiple independent sources and by separating approved clinical use from investigational or unproven commercial claims. Regional, group, and country assessments consider healthcare infrastructure, research intensity, policy frameworks, manufacturing capacity, reimbursement dynamics, ethical governance, clinical trial activity, and transplant readiness to provide a balanced view of stem cell therapy opportunities and risks.

Conclusion

Stem cell therapy is entering a more disciplined phase in which scientific promise must translate into clinically proven, regulator-approved, and economically sustainable therapies. The market's strongest opportunities will come from developers that combine rigorous biology with industrial manufacturing, credible clinical evidence, responsible patient access strategies, and transparent safety surveillance. Hematopoietic stem cell transplantation continues to provide the clinical foundation, while next-generation allogeneic, iPSC-derived, and engineered stem cell products are defining the future pipeline.

Competitive advantage will belong to organizations that can manage complexity across science, regulation, quality, logistics, and reimbursement. As artificial intelligence, automation, and global clinical networks mature, stem cell therapy has the potential to transform treatment paradigms in selected high-need diseases. Success will depend on disciplined execution, validated evidence, ethical commercialization, and a firm commitment to patient safety.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Stem Cell Therapy Market, by Therapy Type

  • 7.1. Allogeneic Therapy
  • 7.2. Autologous Therapy

8. Stem Cell Therapy Market, by Cell Source

  • 8.1. Adult Stem Cells
    • 8.1.1. Hematopoietic Stem Cells
    • 8.1.2. Mesenchymal Stem Cells
    • 8.1.3. Neural Stem Cells
  • 8.2. Embryonic Stem Cells
  • 8.3. Induced Pluripotent Stem Cells
  • 8.4. Perinatal Stem Cells
    • 8.4.1. Amniotic Fluid Stem Cells
    • 8.4.2. Umbilical Cord Stem Cells

9. Stem Cell Therapy Market, by Technology

  • 9.1. Biomaterial Based Therapy
  • 9.2. Ex Vivo Expansion
  • 9.3. Gene Edited Technologies
  • 9.4. Scaffold Based Therapy

10. Stem Cell Therapy Market, by Mode of Administration

  • 10.1. Intra-articular
  • 10.2. Intramuscular
  • 10.3. Intravenous

11. Stem Cell Therapy Market, by Application

  • 11.1. Drug Discovery & Development
  • 11.2. Regenerative Medicine
  • 11.3. Tissue Engineering

12. Stem Cell Therapy Market, by Therapeutic Areas

  • 12.1. Cardiovascular Diseases
  • 12.2. Hematology
  • 12.3. Musculoskeletal Disorders
  • 12.4. Neurological Disorders
  • 12.5. Oncology

13. Stem Cell Therapy Market, by End User

  • 13.1. Academic & Research Institutes
  • 13.2. Biopharmaceutical Companies
  • 13.3. Hospitals & Clinics
  • 13.4. Stem Cell Banks

14. Stem Cell Therapy Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Stem Cell Therapy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Stem Cell Therapy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Anterogen Co., Ltd.
  • 18.2. Astellas Pharma Inc.
  • 18.3. Beike Biotechnology Co., Ltd.
  • 18.4. BrainStorm Cell Therapeutics Inc.
  • 18.5. Bristol-Myers Squibb Company
  • 18.6. CellProthera SAS
  • 18.7. Cynata Therapeutics Limited
  • 18.8. Fate Therapeutics, Inc.
  • 18.9. Gamida Cell Ltd.
  • 18.10. Garuda Therapeutics
  • 18.11. Holostem Terapie Avanzate S.r.l.
  • 18.12. Jasper Therapeutics, Inc.
  • 18.13. JCR Pharmaceuticals Co., Ltd.
  • 18.14. Juvena Therapeutics Inc.
  • 18.15. Kangstem Biotech Co., Ltd.
  • 18.16. Kite Pharma, Inc. by Gilead Sciences, Inc.
  • 18.17. Lonza Group AG
  • 18.18. Medeze Group
  • 18.19. Merck KGaA
  • 18.20. Mesoblast Ltd.
  • 18.21. Novo Nordisk A/S
  • 18.22. Plasticell
  • 18.23. Pluri Inc.
  • 18.24. ReNeuron Group PLC
  • 18.25. SQZ Biotechnologies Company by Stemcell Technologies
  • 18.26. Takara Bio Inc.
  • 18.27. Thermo Fisher Scientific Inc.
  • 18.28. U.S. Stem Cell Inc
  • 18.29. Umoja Biopharma
  • 18.30. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL STEM CELL THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL STEM CELL THERAPY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL STEM CELL THERAPY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL STEM CELL THERAPY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALLOGENEIC THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALLOGENEIC THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALLOGENEIC THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOLOGOUS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOLOGOUS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOLOGOUS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ADULT STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADULT STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ADULT STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEMATOPOIETIC STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEMATOPOIETIC STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEMATOPOIETIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEURAL STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEURAL STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEURAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PERINATAL STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PERINATAL STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PERINATAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AMNIOTIC FLUID STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AMNIOTIC FLUID STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AMNIOTIC FLUID STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL UMBILICAL CORD STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL UMBILICAL CORD STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL UMBILICAL CORD STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOMATERIAL BASED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOMATERIAL BASED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOMATERIAL BASED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EX VIVO EXPANSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EX VIVO EXPANSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EX VIVO EXPANSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE EDITED TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE EDITED TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE EDITED TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SCAFFOLD BASED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SCAFFOLD BASED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SCAFFOLD BASED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRA-ARTICULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTRA-ARTICULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRA-ARTICULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HEMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HEMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MUSCULOSKELETAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MUSCULOSKELETAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MUSCULOSKELETAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL STEM CELL BANKS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL STEM CELL BANKS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL STEM CELL BANKS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 176. GCC STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. GCC STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. GCC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. G7 STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 205. G7 STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. G7 STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. G7 STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. G7 STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. NATO STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. NATO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 216. NATO STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. NATO STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. NATO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. CANADA STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 235. CANADA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 236. CANADA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 237. CANADA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. CANADA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. CANADA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. MEXICO STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 245. MEXICO STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 246. MEXICO STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 247. MEXICO STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. MEXICO STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. MEXICO STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 251. MEXICO STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. BRAZIL STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 255. BRAZIL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 256. BRAZIL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 257. BRAZIL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. BRAZIL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. BRAZIL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 261. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. GERMANY STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 275. GERMANY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 276. GERMANY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 277. GERMANY STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. GERMANY STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. GERMANY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. FRANCE STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 285. FRANCE STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 286. FRANCE STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 287. FRANCE STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. FRANCE STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. FRANCE STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 291. FRANCE STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. RUSSIA STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 295. RUSSIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 296. RUSSIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 297. RUSSIA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. RUSSIA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 299. RUSSIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 301. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. ITALY STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 305. ITALY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 306. ITALY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 307. ITALY STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. ITALY STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. ITALY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 310. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 311. ITALY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. SPAIN STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 315. SPAIN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 316. SPAIN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 317. SPAIN STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 318. SPAIN STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. SPAIN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 320. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 321. SPAIN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 332. INDIA STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 333. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. INDIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 335. INDIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 336. INDIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 337. INDIA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 338. INDIA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 339. INDIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 340. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 341. INDIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 342. JAPAN STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 343. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. JAPAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 345. JAPAN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 346. JAPAN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 347. JAPAN STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 348. JAPAN STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 349. JAPAN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 350. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 351. JAPAN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 352. AUSTRALIA STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 353. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 354. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 355. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 356. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 357. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 358. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 359. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 360. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 361. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 362. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 363. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 364. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 20